Data from three pivotal phase III studies—CLL14, MURANO and VIALE-A—of Venclexta (venetoclax) support the primary analysis of Venclexta in chronic lymphocytic leukemia and the possibility of tailoring treatment approaches based on genetic risk factors.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe